These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15902519)

  • 1. Infliximab as monotherapy in giant cell arteritis.
    Uthman I; Kanj N; Atweh S
    Clin Rheumatol; 2006 Feb; 25(1):109-10. PubMed ID: 15902519
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs.
    Airò P; Antonioli CM; Vianelli M; Toniati P
    Rheumatology (Oxford); 2002 Mar; 41(3):347-9. PubMed ID: 11934977
    [No Abstract]   [Full Text] [Related]  

  • 3. Infliximab efficiency and failure.
    Rozin AP
    Ann Rheum Dis; 2004 Jun; 63(6):751-2; author reply 752. PubMed ID: 15140791
    [No Abstract]   [Full Text] [Related]  

  • 4. Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis.
    Andonopoulos AP; Meimaris N; Daoussis D; Bounas A; Giannopoulos G
    Ann Rheum Dis; 2003 Nov; 62(11):1116. PubMed ID: 14583578
    [No Abstract]   [Full Text] [Related]  

  • 5. Summaries for patients. Adding infliximab to the treatment regimen for giant cell arteritis.
    Ann Intern Med; 2007 May; 146(9):I12. PubMed ID: 17470826
    [No Abstract]   [Full Text] [Related]  

  • 6. Tumor necrosis factor blocking agents in polymyalgia rheumatica and giant cell arteritis.
    Salvarani C; Hunder GG
    Ann Intern Med; 2008 Jan; 148(2):167-8; author reply 168. PubMed ID: 18195345
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of polymyalgia rheumatica and giant cell arteritis: are we any further forward?
    Luqmani R
    Ann Intern Med; 2007 May; 146(9):674-6. PubMed ID: 17470835
    [No Abstract]   [Full Text] [Related]  

  • 8. [First scientific meeting of CRI (Rheumatism and Inflammation Club) under the patronage of FNSIM (French National Society of Internal Medicine) and FSR(French Society of Rheumatology) Paris, May 4, 2002].
    Grateau G; Geffray L; Veyssier-Belot C
    Rev Med Interne; 2002 Oct; 23(10):805-7. PubMed ID: 12428480
    [No Abstract]   [Full Text] [Related]  

  • 9. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial.
    Hoffman GS; Cid MC; Rendt-Zagar KE; Merkel PA; Weyand CM; Stone JH; Salvarani C; Xu W; Visvanathan S; Rahman MU;
    Ann Intern Med; 2007 May; 146(9):621-30. PubMed ID: 17470830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases.
    Cantini F; Niccoli L; Salvarani C; Padula A; Olivieri I
    Arthritis Rheum; 2001 Dec; 44(12):2933-5. PubMed ID: 11762955
    [No Abstract]   [Full Text] [Related]  

  • 11. Infliximab in Takayasu arteritis: a safe alternative?
    Karageorgaki ZT; Mavragani CP; Papathanasiou MA; Skopouli FN
    Clin Rheumatol; 2007 Jun; 26(6):984-7. PubMed ID: 16633710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two Takayasu arteritis patients successfully treated with infliximab: a potential disease-modifying agent?
    Della Rossa A; Tavoni A; Merlini G; Baldini C; Sebastiani M; Lombardi M; Neglia D; Bombardieri S
    Rheumatology (Oxford); 2005 Aug; 44(8):1074-5. PubMed ID: 15840604
    [No Abstract]   [Full Text] [Related]  

  • 13. Prolonged efficacy of infliximab for refractory adult-onset Still's disease.
    Dilhuydy MS; Vatan R; Etienne G; Longy-Boursier M; Mercié P
    Clin Exp Rheumatol; 2005; 23(1):121-2. PubMed ID: 15789901
    [No Abstract]   [Full Text] [Related]  

  • 14. Infliximab in a child with therapy-resistant systemic vasculitis.
    de Kort SW; van Rossum MA; ten Cate R
    Clin Rheumatol; 2006 Sep; 25(5):769-71. PubMed ID: 16267606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The application of infliximab (Remicade), a chimeric monoclonal antibody, in the treatment of rheumatic diseases.
    Kalden JR
    Isr Med Assoc J; 2000 Dec; 2 Suppl():11-2. PubMed ID: 11344856
    [No Abstract]   [Full Text] [Related]  

  • 16. Switching to adalimumab is effective in a case of neuro-Behcet's disease refractory to infliximab.
    Leccese P; D'Angelo S; Angela P; Coniglio G; Olivieri I
    Clin Exp Rheumatol; 2010; 28(4 Suppl 60):S102. PubMed ID: 20868587
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of tumor necrosis factor-alpha inhibitors on lung lesions with rheumatoid arthritis.
    Inoue K; Takano H; Yanagisawa R; Yoshikawa T
    Chest; 2003 Jul; 124(1):413-4; author reply 414. PubMed ID: 12853558
    [No Abstract]   [Full Text] [Related]  

  • 18. Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab.
    Sfikakis PP; Markomichelakis N; Theodossiadis GP; Grigoropoulos V; Katsilambros N; Theodossiadis PG
    Diabetes Care; 2005 Feb; 28(2):445-7. PubMed ID: 15677814
    [No Abstract]   [Full Text] [Related]  

  • 19. [Improvement in visual acuity in a patient with ischaemic optic neuropathy (Horton arteritis) undergoing therapy with infliximab: a case report].
    Benucci M; Manfredi M; Puce F; Zuccarini S
    Recenti Prog Med; 2007 Dec; 98(12):624-6. PubMed ID: 18369037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of chronic tophaceous gout with infliximab (Remicade).
    Fiehn C; Zeier M
    Rheumatol Int; 2006 Jan; 26(3):274-6. PubMed ID: 15933855
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.